RadNet Reports Record Fourth Quarter and Full Year 2016 Results and Releases 2017 Financial Guidance For the fourth quarter, RadNet reports record Total Net Revenue ("Revenue") of $224.9 million, an

RadNet Reports Record Fourth Quarter and Full Year 2016 Results

and Releases 2017 Financial Guidance

LOS ANGELES, California, March 14, 2017

- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic

imaging services through a network of 305 owned and/or operated outpatient imaging centers, today reported financial results for

its fourth quarter and full year ended December 31, 2016.

Fourth Quarter Report:

For the fourth quarter of 2016, RadNet reported

Revenue of $224.9 million, Adjusted EBITDA(1) of $34.9 million and Net Income of $3.7. Revenue increased $9.2 million

(or 4.3%), Adjusted EBITDA(1) increased $2.3 million (or 7.2%) and Net Income increased $2.8 million over the fourth

Net Income for the fourth quarter was $0.08

per diluted share, compared to a Net Income of $0.02 per diluted share in the fourth quarter of 2015. These per share values are

based upon a weighted average number of diluted shares outstanding of 46.4 million in the fourth quarter of 2016 and 46.5 million

of diluted shares outstanding in the fourth quarter of 2015.

Affecting Net Income

in the fourth quarter of 2016 were certain non-cash expenses and non-recurring items including: $908,000 of non-cash employee stock

compensation expense resulting from the vesting of certain options and restricted stock; $349,000 of severance paid in connection

with headcount reductions related to cost savings initiatives; $392,000 loss on the disposal of certain capital equipment; and

$801,000 of amortization and write off of deferred financing costs and loan discount related to our

existing credit facilities.

For the fourth quarter of 2016, as compared

with the prior year's fourth quarter, MRI volume increased 2.6%, CT volume increased 3.1% and PET/CT volume increased 4.0%.

Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased

0.6% over the prior year's fourth quarter. On a same-center basis, including only those centers which were part of RadNet

for both the fourth quarters of 2016 and 2015, MRI volume increased 1.5%, CT volume increased 1.7% and PET/CT volume increased

4.0%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other

exams, was flat over the prior year's same quarter.

Dr. Howard Berger, President and Chief Executive

Officer of RadNet, commented "I am very pleased with our fourth quarter results. As compared with last year's same

quarter, aggregate Revenue, EBITDA, Net Income and procedural volumes increased. Our same center advanced modalities and Revenue

also grew in the current quarter over last year's fourth quarter. Although we are not complete with our efforts, during the

quarter we made significant progress in integrating our recently acquired operations of Diagnostic Imaging Group and New York Radiology

Partners. These efforts included migrating billing and site-level clinical systems, evaluating, training and enhancing the capabilities

of personnel, revamping marketing and branding strategies and migrating supply relationships and vendor contracts."

For full year 2016, the Company reported Revenue

of $884.5 million, Adjusted EBITDA(1) of $133.0 million and Net Income of $7.2 million. Revenue increased $74.9 million

(or 9.3%) and Adjusted EBITDA(1) increased $11.4 million (or 9.3%). Net Income for 2016 was $0.15 per diluted share,

compared to Net Income of $0.17 per diluted share in 2015 (based upon a weighted average number of diluted shares outstanding of

46.7 million and 45.2 million in 2016 and 2015, respectively).

Affecting Net Income

in 2016 were certain non-cash expenses and non-recurring items including: $5.8 million of non-cash employee stock compensation

expense resulting from the vesting of certain options and restricted stock; $2.9 of severance paid in connection with headcount

reductions related to cost savings initiatives; $767,000 loss on the disposal of certain capital equipment; $5.0 million gain on

the return of common stock related to one of our acquisitions; and $5.0 million of amortization and

write off of deferred financing fees and discount on issuance of debt related to our existing credit facilities and refinancing

For the year ended December 31, 2016, as compared

to 2015, MRI volume increased 7.8%, CT volume increased 7.9% and PET/CT volume increased 7.9%. Overall volume, taking into account

routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 8.3% for the twelve months of 2016

"During 2016, we focused on internal

operations and completed no material acquisitions. I'm proud of our many operational and financial accomplishments during

the year. First, throughout 2016, we materially improved our balance sheet and financial leverage ratios. We generated over $35

million of free cash flow, ended the year with a cash balance of over $20 million and reduced our net debt by over $20 million

as compared with its balance on December 31, 2015. We were able to significantly reduce our Net Debt to EBITDA leverage to 4.8x,

down from 5.3x just one year ago," concluded Dr. Berger.

"Another key accomplishment in 2016 was

the announcement of our first West Coast health system joint venture with Dignity Health in Glendale, CA. We are now fully operational

with the two centers we own jointly. We are actively working on additional health system partnerships on both coasts and look forward

to announcing their successful formation during 2017. Also during 2016, we laid the foundation to bring our West Coast Breastlink

operations to two of our larger East Coast markets. Throughout the year, we assembled the team, business plan and site locations

for a comprehensive breast disease management offering we expect to become fully operational in the second quarter of 2017,"

"Additionally, subsequent to quarter

end, we successfully completed an amendment to our senior credit facilities which reduced our interest rate by 0.5% on our $478.9

million senior secured first lien term loan and $117.5 million senior secured revolving credit facility. This amounts to approximately

$2.4 million of interest expense savings, providing additional cash flow which we will use to further de-lever our balance sheet

or expand our business."

Actual Results vs. 2016 Guidance:

The following compares the Company's

actual 2016 performance with previously announced revised guidance levels.

2017 Fiscal Year Guidance

For its 2017 fiscal year, RadNet announces

its guidance ranges as follows:

Dr. Berger commented, "We have many reasons

to be optimistic about 2017. First, 2017 is the second year since 2006 that we will avoid a negative reimbursement impact from

Medicare. Second, we will complete the vast majority of integration efforts related to New York Radiology Partners and Diagnostic

Imaging Group acquisitions. Third, we will be launching Breastlink operations in two of our East Coast regions. Fourth, we expect

additional Revenue in 2017 from our continued adoption of 3D breast imaging. And, lastly, we expect to begin operations in 2017

of new health system joint ventures."

Conference Call for Today

Dr. Howard Berger, President and Chief Executive

Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call today, at 10:30 a.m.

Eastern Time. During the call, management will discuss the Company's 2016 fourth quarter and year-end results.

Conference Call Details:

Date: Tuesday, March 14, 2017

Dial In-Number: 888-801-6507

International Dial-In Number: 913-312-0660

There will also be simultaneous and archived webcasts available

at http://public.viavid.com/index.php?id=123283

or http://www.radnet.com under the "About RadNEt" menu

section and "News & Press Releases" sub-menu of the website. An archived replay of the call will also be available

and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671

for international callers, and using the passcode 2430393.

Regulation G: GAAP and Non-GAAP Financial

This release contains certain financial information

not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company

believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance.

The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring

charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters.

Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable